title: [Diagnosis, care, and therapeutic possibilities in intravascular B-cell lymphoma--a case report].
abstract: The cutaneous angiotropic lymphoma has a poor prognosis. The diagnosis and the treatment are usually late. The mortality rate is over 80% and the majority of patients die within a year because of the tumorous infiltration of parenchymal organs. The authors report here the medical history and follow up of a still living patient suffering from cutaneous angiotropic lymphoma which has been diagnosed sixty months ago. During the successful treatment course systemic treatment with psoralen ultraviolet A-rays, chlorambucil and cyclophosphamide-doxorubicin-vincristine-methylprednisolone chemotherapy was applied, and for the management of the last relapse, rituximab-cyclophosphamide-doxorubicin-vincristine-methylprednisolone polychemotherapy was used. On the basis of findings in this case a treatment using an anti-CD20 monoclonal antibody could be a promising therapeutic alternative in the management of angiotropic B-cell lymphoma which otherwise considered to be a rare entity.
authors.affiliation: Semmelweis Kórház, II, Belgyógyászati és Haematologiai Osztály, Miskolc. itakacs.2bel@semmelweis-miskolc.hu
authors.forename: István
authors.initials: I
authors.lastname: Takács
authors.forename: László
authors.initials: L
authors.lastname: Tordai
authors.forename: Nóra
authors.initials: N
authors.lastname: Eros
authors.forename: István
authors.initials: I
authors.lastname: Mórocz
authors.forename: Ferenc
authors.initials: F
authors.lastname: Bozsó
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Károlyi
authors.forename: Gáspár
authors.initials: G
authors.lastname: Radványi
authors.forename: Andras
authors.initials: A
authors.lastname: Matolcsy
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005363:Ficusin / Q000627:therapeutic use; D005434:Flow Cytometry; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D008775:Methylprednisolone / Q000008:administration & dosage; D017319:Photosensitizing Agents / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome; D014466:Ultraviolet Rays; D019043:Vascular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D017319:Photosensitizing Agents; D002699:Chlorambucil; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005363:Ficusin; D008775:Methylprednisolone